Research type:
|
HTA Technology Assessment Report |
Title (lead author) etc:
|
The clinical effectiveness and cost-effectiveness of gemcitabine for metastatic breast cancer: a systematic review and economic evaluation (Takeda) 80 pages, Volume 11, number 19 |
DOI
|
10.3310/hta11190 |
View/print executive summary
View/print abstract
View full text in pdf format (507 KB)
 This title is available on our CD-ROM of the journal.
 Order a CD-ROM - free of charge worldwide.
Outputs from this project
- Takeda, A; Jones, J; Loveman, E; Tan, SC; Clegg ,AJ.
The clinical and cost effectiveness of gemcitabine for metastatic breast cancer: a systematic review and economic evaluation. Health Technology Assessment 2007; 11(19):1-6.
- Jones, J; Takeda, A; Tan, SC; Cooper, K; Loveman, E; Clegg, A.
Gemcitabine for the treatment of metastatic breast cancer. Health Technology Assessment 2009;13(suppl 2):1-7.
Go to our correspondence page to comment on this publication
|
Headline: |
The evidence from this review may indicate that treatment with gemcitabine and paclitaxel confers an improved outcome for breast cancer patients in terms of survival and disease progression, but at the cost of increased toxicity and at an expense higher than would usually be considered cost-effective. |
Project ref: |
06/19/01 |
Original project title: |
The clinical effectiveness and cost-effectiveness of gemcitabine for metastatic breast cancer: a systematic review and economic evaluation |
Chief Investigator: |
Southampton Health Technology Assessment Centre (SHTAC), University of Southampton
|
Start Date: |
January 2006 |
Date of publication in HTA journal series |
May 2007
|
Cost: |
This project was commissioned by the HTA programme on a call-off contract basis. |
MeSH* index primary terms: |
BREAST-NEOPLASMS Q-drug-therapy; BREAST-NEOPLASMS Q-economics; BREAST-NEOPLASMS Q-secondary; ANTINEOPLASTIC-COMBINED-CHEMOTHERAPY-PROTOCOLS Q-therapeutic-use (* = Medical Subject Headings) |
MeSH* index secondary terms: |
HUMANS; GEMCITABINE Q-administration-&-dosage; PACLITAXEL Q-administration-&-dosage; FEMALE; COST-BENEFIT-ANALYSIS (* = Medical Subject Headings) |
NRR* number, if applicable: |
N0484179649 (*National Research Register) The National Research Register was a public database of ongoing and recently completed research projects funded by, or of interest to, the United Kingdom's National Health Service (NHS). It is now an archive of projects from early 2000 to September 2007. Search the NRR archive. |
Project Protocol: |
Project protocol (pdf format, 118 kbytes)
|
Printed copies of this title despatched:
|
100 (Figures relate to the previous calendar month) |
URL of this page: |
http://www.hta.ac.uk/1517 |
News feeds